{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122342","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.107584+00:00","generated_at":"2026-05-30T04:49:49.456298+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenaya Therapeutics reports Q3 net loss of $25.6M; DSMB clears dose escalation for TN-201 gene therapy","bullets":["Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.","Cash and investments $79.5M; runway expected into H2 2025.","DSMB recommended dose escalation to 6E13 vg/kg for TN-201 in MyPEAK-1; initial Cohort 1 data expected Dec 2024.","Expanded MyPEAK-1 eligibility to include obstructive HCM patients and those without ICDs; baseline biopsy added.","Entered $45M undrawn credit facility with Silicon Valley Bank in August 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122342","json":"https://secwatch.observer/filing/0000950170-24-122342.json","markdown":"https://secwatch.observer/filing/0000950170-24-122342.md","text":"https://secwatch.observer/filing/0000950170-24-122342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024122342/0000950170-24-122342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024122342/tnya-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:49:49.456298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}